Browse Studies — Arctuva

Phase 1

A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors

This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors. SKL35502 is …

Selected Advanced Solid TumorsColorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.